Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Denosumab not linked to malignancy risk in patients with osteoporosis

Publish date:: December 4, 2020

Key clinical point: Treatment with denosumab in an osteoporosis dosage is not associated with an increased risk of malignancy with drug exposure of up to 48 months.

Major finding: The risk of malignancy was similar between denosumab (60 mg every 6 months, up to 48 months) and other comparators (absolute risk difference, 0%; risk ratio, 1.08; 95% confidence interval, 0.94-1.24).

Study details: Meta-analysis of 25 randomized controlled trials including 21,523 patients with osteoporosis (10,721 treated with denosumab and 10,802 treated with a comparator).

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Citation: Rosenberg D et al. Osteoporos Int. 2020 Nov 3. doi: 10.1007/s00198-020-05704-6.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Gender surgical outcomes differ following puberty suppression,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Osteoporosis

Risk factors for osteoporosis in CHF patients,

Switching to denosumab prevents osteoporosis progression in postmenopausal women with T2D,

Higher prevalence of periapical lesions in patients with osteoporosis,

Psoriasis tied to increased risk for osteoporosis,

BMD and bone turnover after gastric bypass vs. sleeve gastrectomy,